Try our beta test site
408 studies found for:    "Expanded Access" [STUDY-TYPES]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Available Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Condition: Metastatic Merkel Cell Carcinoma
Intervention: Drug: Avelumab
2 No longer available Treatment With Crizotinib Single Patient Expanded Access IND 134375
Condition: Inflammatory Myofibroblastic Tumour
Intervention: Drug: Crizotinib
3 Available Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Condition: Ovarian Cancer
Intervention: Drug: Olaparib tablets
4 Available Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease
Conditions: Cholestasis;   Liver Diseases
Intervention: Drug: Omegaven
5 Available Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Conditions: Acute Myeloid Leukemia (AML);   FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Intervention: Drug: ASP2215
6 Available Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
Condition: Recurrent GBM
Intervention: Biological: rindopepimut
7 Available Individual Patient Expanded Access-Glembatumumab Vedotin
Condition: Metastatic gpNMB Expressing Triple Negative Breast Cancer
Intervention: Drug: glembatumumab vedotin
8 Available Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
Condition: Cancers With NTRK, ROS1, or ALK Gene Fusions
Intervention: Drug: Entrectinib
9 Temporarily not available Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients
Condition: PSR Ovarian Cancer With a BRCA Mutation
Intervention: Drug: olaparib
10 Available Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome
Conditions: Congenital Myasthenic Syndrome;   Lambert-Eaton Myasthenic Syndrome
Intervention: Drug: 3,4-Diaminopyridine
11 Available Expanded Access to RXDX-105 for Cancers With RET Alterations
Condition: Cancers With RET Alterations
Intervention: Drug: RXDX-105
12 Available Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma
Condition: Ewing Sarcoma
Intervention: Drug: Ganitumab
13 Available Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Intervention: Drug: Niraparib
14 Available Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion
Conditions: Cancer;   Neurotrophic Tyrosine Kinase, Receptor-related Proteins
Intervention: Drug: larotrectinib
15 Available Dupilumab Compassionate Use Study
Condition: Asthma
Intervention: Drug: Dupilumab
16 Temporarily not available A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Conditions: Neuroblastoma;   Pheochromocytoma
Intervention: Drug: 131-I-meta-iodobenzylguanidine
17 Available Study of Cannabidiol for Drug-Resistant Epilepsies
Condition: Drug Resistant Epilepsy
Intervention: Drug: Cannabidiol
18 Temporarily not available Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
Conditions: CMV Viremia;   CMV Disease
Intervention: Biological: Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
19 No longer available Single Patient IND, MLN8237
Condition: Prostate Cancer
Intervention: Drug: MLN8237
20 Available An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC
Conditions: Malignant Neoplasms of Digestive Organs;   Neuroendocrine Tumor;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
Interventions: Drug: 68Ga-DOTATOC;   Procedure: PET/CT

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.